Dose-ranging safety and efficacy study of topical creams containing API 31510 for the treatment of in situ cutaneous squamous cell carcinoma.

Trial Profile

Dose-ranging safety and efficacy study of topical creams containing API 31510 for the treatment of in situ cutaneous squamous cell carcinoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Ubidecarenone (Primary)
  • Indications Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jul 2012 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 07 Apr 2011 Status changed from not yet recruiting to not stated.
    • 07 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top